Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SHR-A2102 plus adebrelimab in muscle-invasive bladder cancer
CTR20250897Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102, adebrelimab in bladder cancer, muscle-invasive bladder cancer (MIBC), sponsored by Hengrui Therapeutics. Started May 2025; status: active.
02
Drugs
SHR-A2102adebrelimab
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on CTR20250897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250897.